Initial preclinical studies demonstrated that CAR Tregs targeting HLA-A2, factor VIII, or myelin oligodendrocyte glycoprotein (MOG) could suppress alloimmunity, autoimmunity against factor VIII in hemophilia, or experimental autoimmune encephalomyelitis, respectively (46–48). This evidence concerns the gene MOG and hemophilia.